P&F Products & Features GmbH Announces Acquisition of AVVie GmbH

P&F Products & Features GmbH (P&F) announced today the acquisition of AVVie GmbH, a move aimed at enhancing its structural heart portfolio with the integration of the AngelValve™ Augmentation System. The financial terms of the transaction remain undisclosed. This acquisition, finalized on August 5, 2026, underscores P&F's commitment to advancing innovative solutions within the medical technology sector, particularly in the treatment of mitral valve disease.

AVVie GmbH, founded by cardiac surgeon Prof. Werner Mohl, has developed the AngelValve™ Augmentation System, a novel transcatheter solution designed to address the significant unmet needs associated with mitral regurgitation. This condition affects over 13 million individuals across Europe and the United States, yet fewer than 5% of patients with moderate to severe cases currently receive treatment. The acquisition aligns with P&F's mission to close this treatment gap and improve the quality of life for millions suffering from this debilitating condition.

The strategic rationale behind the acquisition lies in the potential synergies between P&F and AVVie. By combining AVVie's research and development infrastructure and intellectual property with P&F's extensive capabilities in product development, clinical and regulatory affairs, manufacturing, and commercialization, the newly formed entity is well-positioned to accelerate innovation and reduce development timelines for the AngelValve™ platform. This merger is expected to enhance P&F's competitive edge in the rapidly evolving structural heart therapy market.

The medical technology sector, particularly in the cardiovascular domain, is witnessing a surge in demand for innovative solutions that address complex health issues. As the population ages and the prevalence of heart-related conditions increases, companies like P&F are focusing on expanding their portfolios to meet these challenges. The acquisition of AVVie not only strengthens P&F's offerings but also reinforces its long-term vision of becoming a global leader in structural heart therapy.

In conclusion, the acquisition of AVVie GmbH by P&F Products & Features GmbH represents a significant step forward in the medical technology landscape, particularly in the treatment of mitral valve disease. As the combined organization leverages its strengths to drive innovation, it is poised to make a meaningful impact on patient care and outcomes in this critical area of healthcare. The broader implications of this transaction may signal a trend towards consolidation in the medical technology sector, as companies seek to enhance their capabilities and address the growing demand for effective cardiovascular therapies.